REGULATED INFORMATION
INSIDE INFORMATION
Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-
Market Equity Offering Program
Mont-Saint-Guibert, Belgium - May 22, 2024, 10:10pm CET / 4:10pm ET - Nyxoah SA
(Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical
technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today
that it has reduced the maximum amount of 6,000,000 ordinary shares available
for issuance under its "at-the-market" offering (announced on December
22, 2022) by an amount of 1,569,139 ordinary shares, or share capital of
EUR 269,579 (excluding issuance premium), resulting in (i) a maximum of
4,430,861 ordinary shares to be issued under its "at-the-market" offering, of
which 3,662,699 ordinary shares remain available for issuance, and (ii) an
increase of the authorized capital that is available to the board of directors
by EUR 269,579. For further context, please refer to section 1.5.2 of the May
22, 2024 board report that is available on the investor page of Nyxoah's website
(https://investors.nyxoah.com/financials > Special Reports).
This press release shall not constitute an offer to sell or a solicitation of an
offer to buy any securities of the Company.
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat OSA. Nyxoah's lead solution
is the Genio® system, a patient-centered, leadless and battery-free hypoglossal
neurostimulation therapy for OSA, the world's most common sleep disordered
breathing condition that is associated with increased mortality risk and
cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to its fullest.
Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. All statements that are not statements of historical facts are, or may be
deemed to be, forward-looking statements. Such forward-looking statements may be
identified by words such as "expects," "potential," "could," or similar
expressions that are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words. Forward-
looking statements include express or implied statements relating to, among
other things, Nyxoah's current expectations regarding the Genio® system; planned
and ongoing clinical studies of the Genio® system; the potential advantages of
the Genio® system; Nyxoah's goals with respect to the development, regulatory
pathway and potential use of the Genio® system; the utility of clinical data in
potentially obtaining FDA approval of the Genio® system; the Company's results
of operations, financial condition, liquidity, performance, prospects, growth
and strategies; and statements relating to the offering, including the expected
closing, the anticipated proceeds from the offering and the use thereof. These
statements are neither promises nor guarantees and are subject to a variety of
risks and uncertainties, many of which are beyond Nyxoah's control, which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. In particular, these risks and uncertainties
include, without limitation, risks relating to market conditions and the
Company's inability, or the inability of the underwriters, to satisfy the
conditions for the closing of the offering. Given these uncertainties, the
reader is advised not to place any undue reliance on such forward-looking
statements. Other risks and uncertainties faced by Nyxoah include those
identified under the heading "Risk Factors" in Nyxoah's most recent Annual
Report on Form 20-F filed with the SEC, as well as subsequent filings and
reports filed with the SEC. The forward-looking statements contained in this
press release reflect Nyxoah's views as of the date hereof, and Nyxoah does not
assume and specifically disclaims any obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required by law.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com
Â